Breast cancer is unusual among the common cancers in that a single fact is not enough to plan treatment. Two questions get asked at the same time, and both of them shape the answer. The first is how far the disease has spread. The second is what the tumour is actually made of, which is reported as hormone receptor status and HER2 status. A stage two cancer that is hormone-receptor-positive and a stage two cancer that is triple-negative will be treated with different drugs, different timelines, and different expectations. This article walks through both axes, then puts the costs and the hospitals on top.

Our dedicated breast cancer page collects the treatment pathways, hospitals and reference costs in one place; this post explains the reasoning behind them.

1. The Two Questions

How far has it spread? Staging divides breast cancer into three practical groups. Early-stage disease is confined to the breast and, at most, the lymph nodes under the arm. Locally advanced disease has reached the chest wall or the skin, or has involved lymph nodes higher up. Metastatic disease has spread to distant organs such as bone, liver or lung. The stage decides whether surgery comes first, whether drug treatment comes first, or whether the goal shifts to control rather than cure.

What is the tumour made of? Every breast cancer biopsy is tested for hormone receptors (oestrogen and progesterone) and for HER2, a protein that drives growth. That produces three broad groups: hormone-receptor-positive and HER2-negative, which is the most common; HER2-positive; and triple-negative, where none of the three markers is present. The subtype decides which drugs you are offered. It is not a detail. It changes the regimen.

Both results come from tests you have probably already had. If you are seeking a second opinion, the pathology report and the receptor status are the two documents a Chinese centre will ask for first.

2. The Treatment Path

Early stage. The standard is surgery, and there are two forms. Breast-conserving surgery, often called a lumpectomy, removes the tumour and a margin of surrounding tissue while keeping the breast; it is followed by radiotherapy to the remaining breast. A mastectomy removes the whole breast. Both are usually paired with a sentinel node biopsy, which samples the first lymph node the tumour would drain to rather than removing all of them. For many early tumours, the two operations give equivalent survival, so the choice turns on tumour size, how many areas are involved, and your own preference.

Reconstruction. This is where China's surgical volume shows. Reconstruction can be immediate, performed in the same operation as the mastectomy, or delayed until after other treatment finishes. Immediate reconstruction means one anaesthetic and one recovery, but it is not always offered: if you will need radiation to the chest wall afterwards, many teams prefer to wait, because radiation can distort an implant. Reconstruction divides into implant-based techniques and autologous ones, where the surgeon rebuilds the breast from your own tissue, most often from the abdomen. Autologous reconstruction is a longer operation requiring microsurgery, and it holds up better after radiation.

Locally advanced. Here the order reverses. Chemotherapy comes first, given for several cycles to shrink the tumour before surgery, which is called neoadjuvant treatment. In HER2-positive disease the targeted antibodies are started at the same time. Surgery follows, then radiotherapy, then the remainder of the drug course.

The subtype decides the drugs. Hormone-receptor-positive disease is treated with endocrine therapy, taken as a daily tablet for five to ten years after surgery, sometimes with a targeted agent added. HER2-positive disease receives targeted antibodies, usually given before and after surgery. Triple-negative disease depends on chemotherapy, with immunotherapy added in selected cases. These regimens differ in both cost and duration, which is why the same stage can produce very different bills.

Metastatic. When the disease is beyond the breast and nodes, treatment aims at control rather than cure, and is planned cycle by cycle using the same subtype logic: endocrine therapy with a targeted agent for hormone-receptor-positive disease, antibody therapy for HER2-positive, chemotherapy for triple-negative.

3. What Each Path Costs

Our published reference ranges, with US self-pay figures alongside for comparison. These are estimates; the final quote comes from the hospital after it reviews your pathology and imaging.

What is countedChina referenceUS reference
Breast surgery (mastectomy or lumpectomy)$8,000–$15,000$50,000–$80,000
Full treatment course (surgery + radiotherapy + systemic therapy)$20,000–$40,000$100,000–$180,000

The gap between the two rows is the part patients most often underestimate. Surgery is the visible cost, but a full course adds weeks of radiotherapy and, in many cases, a year or more of drug treatment. Which end of the range you land on depends less on the hospital than on your subtype, because that determines which drugs are in the regimen and for how long.

4. Where Breast Cancer Is Handled

Our directory records the following centres. Every one is recorded as offering international patient services.

  • Cancer Hospital, CAMS (Beijing) — recorded in our directory as first in oncology nationally, with high-volume breast surgery and radiotherapy. See CAMS.
  • Sun Yat-sen University Cancer Center (Guangzhou) — recorded in the national top three for cancer care, and a leading southern centre. See Sun Yat-sen.
  • Fudan University Shanghai Cancer Center (Shanghai) — also recorded in the national top three, with a strong breast surgery department. See Fudan Cancer Center.
  • Fudan University Women's Hospital (Shanghai) — a dedicated obstetrics and gynaecology hospital, recorded as second nationally in that field, and a specialist option for breast surgery. See Fudan Women's.

The full selection logic, including the criteria we apply and what we do not claim, is on our methodology page.

5. What This Does Not Promise

Three honest limits, because a treatable cancer invites overstatement:

  1. Reconstruction is not always available immediately. Whether you can have it in the same operation depends on your tumour, your radiation plan and your general health. A team has to assess you, and for some patients the answer is to wait.
  2. The prices are estimates. Costs move with the drugs in your regimen, and a full course can sit at the top of the range. Get a written quote before committing.
  3. Survival is not something a website can promise. Breast cancer outcomes depend on stage, subtype, biology and how you respond to treatment. No intermediary can predict your result, and you should be sceptical of any that offers to.

The useful frame is this: the value of travelling is access and speed, whether that means a surgical team that performs high volumes of reconstruction, or a treatment slot measured in weeks rather than months.


6. Frequently Asked Questions

How much does breast cancer treatment cost in China?

Our published reference ranges: breast surgery (mastectomy or lumpectomy) runs $8,000–$15,000 in China against $50,000–$80,000 in the US, and a full treatment course adding radiotherapy and systemic therapy runs $20,000–$40,000 against $100,000–$180,000. The final quote depends on your stage, subtype and the drugs your regimen requires.

Can I have breast reconstruction at the same time as the cancer surgery?

Often yes. Immediate reconstruction is performed in the same operation as the mastectomy, which means one anaesthetic and one recovery. Whether it is offered depends on whether you need post-operative radiation, your general health, and the surgical team's assessment. Reconstruction after radiation is usually delayed, and often uses your own tissue rather than an implant.

Which hospitals in China treat breast cancer?

Our directory records the Cancer Hospital of CAMS (Beijing) as first in oncology nationally, with Sun Yat-sen University Cancer Center (Guangzhou) and Fudan University Shanghai Cancer Center both recorded in the national top three. Fudan University Women's Hospital in Shanghai is a dedicated obstetrics and gynaecology hospital and a specialist option for breast surgery. All four are recorded as having international patient services.

Does the subtype of my breast cancer change the treatment?

Yes, and it matters as much as the stage. Hormone-receptor-positive disease is treated with endocrine therapy for five to ten years after surgery. HER2-positive disease adds targeted antibodies, given before or after surgery. Triple-negative disease relies on chemotherapy, with immunotherapy added in selected cases. Two patients with the same stage can receive completely different drug regimens.

How quickly can breast cancer treatment start in China?

Records, pathology and imaging can be reviewed before you travel, and surgery is typically scheduled within two to four weeks once a plan is agreed. If your plan starts with chemotherapy to shrink the tumour first, that can begin on a similar timeline. Your own timing is confirmed after the hospital assesses your records.


Get a Free Breast Cancer Case Review

Send your pathology report, receptor status and recent imaging. We'll tell you which of the centres above fits your stage and subtype, confirm whether immediate reconstruction is realistic in your case, and outline what a written quote would cover. No obligation, 100% confidential, we reply within 24 hours.

  • 📧 Email: contact@chinahospitalsguide.com
  • 💬 WhatsApp: +86 157 6310 7083
  • 📨 Telegram: @chinahospitalguide
  • 💬 WeChat: chinahospitalguide
  • 🌐 Start Free Case Review

Medical Disclaimer This article is general educational content and does not constitute medical advice, a treatment recommendation, or an invitation to seek care. It cannot replace an in-person consultation with a licensed physician. Cost figures are our published reference ranges for international patients and are not guarantees; final quotes come from the hospital after review of your pathology and imaging. Whether a treatment or a reconstruction is suitable must be assessed by a qualified medical team.

Source disclosure The staging and treatment framework follows the NCCN Clinical Practice Guidelines for breast cancer and AJCC 8th edition staging. Hospital rankings are as recorded in our own directory from publicly available national rankings, and are statements about our records rather than independent assessments of clinical quality. Cost ranges are from China Hospitals Guide's published breast cancer and cancer treatment cost guides. China Hospitals Guide is an independent hospital-matching platform and does not accept commissions from hospitals.

Related Reading